You are viewing the site in preview mode

Skip to main content

Table 1 Demographic characteristics of young patients surgically treated between January 1, 2006, and December 31, 2014 (n = 1099)

From: Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases

Characteristics No. of patients (%)
BC family history
 Yes 113 (10.3)
 No 969 (88.2)
 Unknown 17 (1.5)
Reproductive history*
 Yes 827 (75.3)
 No 257 (23.4)
 Unknown 15 (1.4)
Breastfeeding history
 Yes 745 (67.8)
 No 337 (30.7)
 Unknown 17 (1.5)
Tumor size
 T1 420 (38.2)
 T2 508 (46.2)
 T3 88 (8.0)
 T4 16 (1.5)
 Tx 67 (6.1)
Stage
 I 282(25.7)
 II a 383 (34.8)
 II b 159 (14.5)
 III a 126 (11.5)
 III b 8 (0.7)
 III c 97 (8.8)
 Unknown 44 (4.0)
Lymph node metastasis
 N0 585 (53.2)
 N1 276(25.1)
 N2 124 (11.3)
 N3 94 (8.6)
 Unknown 20 (1.8)
Histological grade
Well differentiated 35 (3.2)
 Moderately differentiated 594 (54.0)
 Poorly differentiated 163 (14.8)
 Unknown 307 (27.9)
Pathological type
 Invasive ductal carcinoma 999 (90.9)
 Invasive lobular carcinoma 10 (0.9)
 Others 90 (8.2)
Final surgery
 Breast-conserving surgery 257 (23.4)
 Mastectomy 842 (76.6)
Biomarker subtype
 HR+/HER2− 594 (54.0)
 HR+/HER2+ 120 (10.9)
 HR−/HER2+ 75 (6.8)
 HR−/HER2− 201 (18.3)
 Unknown 109 (9.9)
Neoadjuvant chemotherapy
 Yes 176 (16.0)
 No 923 (84.0)
Adjuvant chemotherapy regimens
 Anthracycline-based 140 (12.7)
 Anthracycline- and taxane-based 884 (80.4)
 Unknown 67 (6.1)
 None 8 (0.7)
Radiotherapy
 Yes 557 (50.7)
 No 453 (41.2)
 Unknown 89 (8.1)
Endocrine therapy
 Yes 589 (53.6)
 No 316 (28.8)
 Unknown 194 (17.7)
Ovarian function suppression
 Yes 187 (17.0)
 No 545 (49.6)
 Unknown 367 (33.4)
Trastuzumab treatment
 Yes 85 (7.7)
 No 836 (76.1)
 Unknown 178 (16.2)
  1. BC, breast cancer; HR+, hormone receptor positive, HR− hormone receptor negative, HER2+ human epidermal growth factor 2 positive, HER2− human epidermal growth factor 2 negative
  2. *Reproductive history: Yes means they had children
\